Pfizer's Thrive-131 Study Fails to Meet Primary Endpoint.

Pfizer has announced that its phase 3 Thrive-131 study did not meet its primary endpoint. The study aimed to evaluate the safety and efficacy of a treatment for a specific medical condition. The company's net sales breakdown shows that primary care products account for 47.4%, specialty care products for 26.2%, oncology products for 24.5%, and other products for 1.9%. The majority of net sales come from the United States, accounting for 60.8%.

New York, NY - Pfizer Inc. (NYSE: PFE) announced on August 15, 2025, that its Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, for the treatment of sickle cell disease (SCD) did not meet its primary endpoint. The study aimed to assess the safety and efficacy of inclacumab in reducing the rate of vaso-occlusive crises (VOCs) in participants aged 16 and older with SCD. Despite the study not achieving its primary goal, inclacumab was well-tolerated among trial participants, with anemia, arthralgia, and back pain being the most commonly reported treatment-emergent adverse events [2].

The results of the THRIVE-131 study are a setback for Pfizer's SCD portfolio, which includes its Phase 3 asset osivelotor and Oxbryta (voxelotor), acquired through a $5.4B deal with Global Blood Therapeutics in 2022. Last year, Oxbryta was pulled from global markets due to safety concerns, and the FDA has imposed a partial clinical hold on enrollments in a Phase 3 trial for osivelotor [2].

Pfizer's latest financial performance highlights the company's resilience and strategic focus. Despite revenue and profit declines post-pandemic, Pfizer has managed to sustain its generous dividend, with a yield of 7.3% as of July 2025. The company's strong dividend has been supported by prudent financial management and a focus on growth in oncology and specialty drugs, which accounted for 24.5% and 26.2% of net sales, respectively, in the latest period [3].

Looking ahead, Pfizer's stock price valuation of 8 times the midpoint of its 2025 earnings guidance and potential growth in oncology and specialty drugs position the company as a potential investment opportunity for income-focused investors and bargain hunters. However, investors should remain cautious and consider the broader market sentiment and potential regulatory headwinds, such as tariffs and pressure to cut prescription drug prices [3].

References:
[1] https://www.marketscreener.com/news/pfizer-provides-update-on-phase-3-inclacumab-study-for-the-treatment-of-people-with-sickle-cell-di-ce7c51dedf8ff424
[2] https://seekingalpha.com/news/4486173-pfizer-trial-sickle-cell-disease-therapy-fails
[3] https://finance.yahoo.com/news/meet-7-3-yield-dividend-100500627.html